Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial

Seminars in Oncology

Volumn 33, Issue SUPPL. 7, 2006, Pages 8-12

  Goss, Paul E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ESTROGEN SYNTHESIS; FOLLOW UP; HOT FLUSH; HUMAN; METASTASIS; MORTALITY; MYALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 33646789495     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.025     Document Type: Article

References (22)

1. Dunn B.K., Wickerham D.L., and Ford L.G. Prevention of hormone-related cancers. breast cancer. J Clin Oncol 23 (2005) 357-367
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer. An overview of the randomized trials. Lancet 351 (1998) 1451-1467
3. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer. Status report 2002. J Clin Oncol 20 (2002) 3317-3327
4. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer. Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
5. Hortobagyi G.N., Kau S.-W., Buzdar A.U., et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. Proc Am Soc Clin Oncol 22 (2004) 23 (abstr)
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomised trials. Lancet 365 (2005) 1687-1717
7. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer. Status report 2004. J Clin Oncol 23 (2005) 1-11
8. Geisler J., Haynes B., Anker G., et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
9. Lu Q., Yue W., Wang J., et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 50 (1998) 63-71
10. Brodie A., Lu Q., Liu Y., and Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 6 (1999) 205-210
11. Eiermann W., Paepke S., Appfelstaedt J., et al. Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
12. Mouridsen H.T., and Robert N.J. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 41 (2005) 1678-1689
13. Goss P.E. Changing clinical practice. Extending the benefits of adjuvant endocrine therapy in breast cancer. Semin Oncol 31 suppl (2004) 15-22
14. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16 (2005) 707-715
15. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years (yrs) of adjuvant tamoxifen. NCIC CTG MA.17b. Breast Cancer Res Treat 88 suppl 1 (2004) S36 (abstr 404)
16. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
17. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer. Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
18. Goss P.E., Ingle J.N., Martino S., et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 22 (2004) 88 (abstr)
19. Kaufman M., and Rody A. Long-term risk of breast cancer recurrence. the need for extended adjuvant therapy. J Cancer Res Clin Oncol 131 (2005) 487-494
20. Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 23 suppl (2005) 62s (abstr 738)
21. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17. A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 (2005) 6931-6940
22. Brufsky A., Harker G., Beck T., et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let). 12 Months BMD results of the Z-FAST trial. Proc Am Soc Clin Oncol 23 (2005) 12S (abstr 533)